Dr. Harvey Risch is a practicing epidemiologist with more than 30 years of experience researching the etiology of cancer, including ovarian cancer. Dr. Risch has been a member of the Society for Epidemiologic Research since 1982, the American Society of Preventive Oncology since 1984, and elected Fellow of the American College of Epidemiology since 1991. Dr. Risch received a Bachelor of Science degree in mathematics and biology from the California Institute of Technology in 1972 and completed medical training at UC San Diego School of Medicine in 1976. He then completed a PhD in biomathematics in 1980 at the University of Chicago, where his dissertation work involved mathematical solutions for the general stochastic epidemic model, on which he has published in the peer-reviewed scientific literature. In 1983, Dr. Risch moved to the University of Toronto, where he was Assistant and then Associate Professor, before moving in 1991 to Yale School of Public Health, becoming Professor of Epidemiology in 2001.
Dr. Risch has published more than 350 peer-reviewed original research papers in very well-regarded scientific journals and has an h-index of 96, with more than 41,800 publication citations to-date. Dr. Risch has served as peer reviewer for more than 50 scientific and medical journals. Dr. Risch has been Associate Editor of the Journal of the National Cancer Institute since 2000, Member of the Board of Editors of the American Journal of Epidemiology from 2014-2020, and Editor of the International Journal of Cancer since 2008.
In May 2020, Dr. Risch published the seminal paper on early treatment of high-risk outpatients in the American Journal of Epidemiology (https://doi.org/10.1093/aje/kwaa093), which has been downloaded almost 90,000 times and viewed by 150,000. Dr. Risch was senior author on the out-patient treatment clinical trial study in Brazil (https://doi.org/10.1016/j.tmaid.2020.101906), and has co-authored with Dr. Peter McCullough two papers that form the now-standard understanding of early outpatient Covid-19 management (https://doi.org/10.1016/j.amjmed.2020.07.003 and https://rcm.imrpress.com/EN/10.31083/j.rcm.2020.04.264).
In 2018, Dr. Risch received two prestigious awards for his cancer research: the “Best of the AACR Journals” award for “Aspirin Use and Reduced Risk of Pancreatic Cancer,” one of the most highly cited Cancer Epidemiology, Biomarkers & Prevention articles published in 2016 (April 2018) ( http://aacrjournals.org/h-a-risch-bio ), and the international Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research, ( http://columbiasurgery.org/pancreas/ruth-leff-siegel-award ), $50,000 cash stipend prize. Dr. Risch is an elected member of the Connecticut Academy of Science and Engineering.
